Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website http://www.thejh.org

Case Report

Volume 8, Number 3, September 2019, pages 132-136

Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report

Figures

Figure 1.
Figure 1. Primary cutaneous anaplastic large cell lymphoma. A dense, cellular infiltrate fills the dermis (H&E, × 20) (a) comprised of cells with uniform CD30 expression (× 20) (b). The overlying epidermis and follicular epithelium exhibit a reactive pseudoepitheliomatous hyperplasia mimicking squamous cell carcinoma (H&E, × 100) (c). Large, pleomorphic and mitotically active cells with bizarre nuclear contours predominate below the epidermal changes (H&E, × 200) (d). The markedly atypical cells exhibited an immunophenotype consistent with lymphoma. Higher power magnification of CD30 highlighting lesional cells (× 200) (e). The tumor cells were negative for ALK, CD20 and CD56, EBER, cytokeratin, 34BetaE12, and p63 (not shown). H&E: hematoxylin-eosin; ALK: anaplastic lymphoma kinase; EBER: Epstein-Barr virus-encoded small RNA.
Figure 2.
Figure 2. Rapidly growing tumor extending to left medial canthus, 1 week prior to first cycle of brentuximab vedotin (a). Resolution of primary tumor following three cycles of brentuximab vedotin and 20 fractions of radiation therapy (b). Relapse on left distal leg within 7 months of achieving complete clinical response with CMT (c). Progression of tumor following three cycles of CEOP (d). Left distal leg lesion following six cycles of brentuximab vedotin and radiation therapy (e). CMT: combined modality treatment; CEOP: cyclophosphamide, etoposide, vincristine and prednisone.